Johnson & Johnson Marketable Securities (Current)
Johnson & Johnson (JNJ) had Marketable Securities (Current) of $336.00 million as of 2026-06-28, per its 10-Q filed 2026-07-23.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Short-Term Investments
us-gaap:MarketableSecuritiesCurrent · last filed 2026-07-23
- 2026-06-28: Marketable Securities, Current $336.00M.
- 2026-03-29: Marketable Securities, Current $363.00M.
- 2025-12-28: Marketable Securities, Current $393.00M.
- 2025-09-28: Marketable Securities, Current $331.00M.
| Period end | Marketable Securities, Current |
|---|---|
| 2026-06-28 | $336.00M 10-Q · filed 2026-07-23 |
| 2026-03-29 | $363.00M 10-Q · filed 2026-04-22 |
| 2025-12-28 | $393.00M 10-Q · filed 2026-07-23 |
| 2025-09-28 | $331.00M 10-Q · filed 2025-10-22 |
| 2025-06-29 | $303.00M 10-Q · filed 2025-07-24 |
| 2025-03-30 | $307.00M 10-Q · filed 2025-04-23 |
| 2024-12-29 | $417.00M 10-K · filed 2026-02-11 |
| 2024-09-29 | $317.00M 10-Q · filed 2024-10-23 |
| 2024-06-30 | $597.00M 10-Q · filed 2024-07-25 |
| 2024-03-31 | $745.00M 10-Q · filed 2024-05-01 |
| 2023-12-31 | $1.07B 10-K · filed 2025-02-13 |
| 2023-10-01 | $3.78B 10-Q · filed 2023-10-27 |
| 2023-07-02 | $7.32B 10-Q · filed 2023-07-31 |
| 2023-04-02 | $5.44B 10-Q · filed 2023-04-28 |
| 2023-01-01 | $9.39B 10-K · filed 2024-02-16 |
| 2022-10-02 | $22.72B 10-Q · filed 2022-10-27 |
| 2022-07-03 | $21.59B 10-Q · filed 2022-07-29 |
| 2022-04-03 | $19.93B 10-Q · filed 2022-04-29 |
| 2022-01-02 | $17.12B 10-K · filed 2023-02-16 |
| 2021-10-03 | $13.40B 10-Q · filed 2021-10-29 |
| 2021-07-04 | $10.97B 10-Q · filed 2021-07-29 |
| 2021-04-04 | $11.95B 10-Q · filed 2021-04-30 |
| 2021-01-03 | $11.20B 10-K · filed 2022-02-17 |
| 2020-09-27 | $11.82B 10-Q · filed 2020-10-23 |
| 2020-06-28 | $7.96B 10-Q · filed 2020-07-24 |
| 2020-03-29 | $2.49B 10-Q · filed 2020-04-29 |
| 2019-12-29 | $1.98B 10-K · filed 2021-02-22 |
| 2019-09-29 | $1.70B 10-Q · filed 2019-10-28 |
| 2019-06-30 | $902.00M 10-Q · filed 2019-07-29 |
| 2019-03-31 | $602.00M 10-Q · filed 2019-05-01 |
| 2018-12-30 | $1.58B 10-K · filed 2020-02-18 |
| 2018-09-30 | $3.31B 10-Q · filed 2018-10-31 |
| 2018-07-01 | $570.00M 10-Q · filed 2018-08-02 |
| 2018-04-01 | $565.00M 10-Q · filed 2018-05-01 |
| 2017-12-31 | $472.00M 10-K · filed 2019-02-20 |
| 2017-10-01 | $510.00M 10-Q · filed 2017-11-02 |
| 2017-07-02 | $255.00M 10-Q · filed 2017-08-03 |
| 2017-04-02 | $18.43B 10-Q · filed 2017-05-08 |
| 2017-01-01 | $22.93B 10-K · filed 2018-02-21 |
| 2016-10-02 | $22.23B 10-Q · filed 2016-11-04 |
| 2016-07-03 | $23.94B 10-Q · filed 2016-08-04 |
| 2016-04-03 | $25.99B 10-Q · filed 2016-05-10 |
| 2016-01-03 | $24.64B 10-K · filed 2017-02-27 |
| 2015-09-27 | $23.67B 10-Q · filed 2015-10-30 |
| 2015-06-28 | $23.32B 10-Q · filed 2015-07-31 |
| 2015-03-29 | $19.33B 10-Q · filed 2015-05-01 |
| 2014-12-28 | $18.57B 10-K · filed 2016-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |